
Actor portrayal.
Patients with mNSCLC who have progressed on or after a platinum-based regimen may be eligible for Optune Lua earlier than you think1
✓ Currently receiving maintenance IO after a platinum + IO regimen
✓ Now showing signs of disease progression, but continuing maintenance IO based on clinical judgment
Optune Lua + PD-1/PD-L1 may be an appropriate FDA-approved option for this patient1
Meet David, a patient with slow progression during maintenance IO


24% reduction in the risk of death1
HR: 0.76 (95% CI: 0.58-0.99); P=0.041
Demonstrating a statistically significant OS improvement in mNSCLC with progression on or after a platinum-based regimen.1,2
Review the pivotal LUNAR studyOptune Lua did not add systemic toxicity. Dermatologic adverse events (dAEs) were the only device-related AEs (occurring in >5% of patients), and were observed in 63.1% of patients (n=89/141)1,3
- Majority were mild-to-moderate (grade 1 to 2)1
- Only 6 patients (4%) reported a grade 3 skin toxicity that required a break from treatment; in all cases the skin issue resolved1
- There were no grade 4 or grade 5 toxicities related to Optune Lua, and no device-related AEs that caused death1
The LUNAR Study was a phase 3, open-label, randomized study testing the safety and effectiveness of Optune Lua together with a PD-1/PD-L1 inhibitor or docetaxel for patients with mNSCLC who progressed on or after platinum-based therapy (N=291)1,*
- Patients were randomized 1:1 to receive either Optune Lua + a PD-1/PD-L1 inhibitor or docetaxel vs a PD-1/PD-L1 inhibitor or docetaxel alone
- Primary endpoint: OS with Optune Lua + a PD-1/PD-L1 inhibitor or docetaxel vs a PD-1/PD-L1 inhibitor or docetaxel alone

Actor portrayal.
An innovative approach in a challenging treatment landscape
Optune Lua is a noninvasive, wearable treatment designed to fit into your patient's everyday life1

Optune Lua uses electrical fields to disrupt cancer cell viability without affecting healthy cells1
Designed for use concurrently with a PD-1/PD-L1 inhibitor or docetaxel

Actor portrayals.
Partnering with your patients and practice at every step of the journey
MyNovocure® is here to help with points of contact and personalized assistance for your practice and your patients who are prescribed Optune Lua
*After interim analysis, the independent data monitoring committee recommended reducing patient accrual to 276 patients with 12 months follow-up. Initial planned accrual was 534 patients with 18 months follow-up. The final enrollment was 291. The expected hazard ratio for overall survival was <0.75.1,4
IO, immune-oncology; mNSCLC, metastatic non–small cell lung cancer; mOS, median overall survival; NSCLC, non–small cell lung cancer; OS, overall survival; PD-1/PD-L1, programmed cell death 1 protein/programmed cell death 1 ligand 1.
References: 1. Optune Lua for Non-Small Cell Lung Cancer (NSCLC). Physician Instructions for Use. Novocure; 2024. 2. Novocure Data on File 2024. US-DOF-0040. 3. Novocure Data on File 2024. US-DOF-0042. 4. Leal T, Kotecha R, Ramlau R, et al. Lancet Oncol. 2023;24(9):1002-1017. 5. Leal T, Kotecha R, Ramlau R, et al. Supplementary appendix. Lancet Oncol. 2023;24(9):1002-1017. Accessed March 21, 2024. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00344-3/fulltext